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Abstract
Concurrently with a workshop sponsored by the National Cancer Institute, we identified key 
“drivers” for accelerating cancer epidemiology across the translational research continuum in the 
21st century: emerging technologies, a multilevel approach, knowledge integration, and team 
science. To map the evolution of these “drivers” and translational phases (T0–T4) in the past 
decade, we analyzed cancer epidemiology grants funded by the National Cancer Institute and 
published literature for 2000, 2005, and 2010. For each year, we evaluated the aims of all new/
competing grants and abstracts of randomly selected PubMed articles. Compared with grants 
based on a single institution, consortium-based grants were more likely to incorporate 
contemporary technologies (P = 0.012), engage in multilevel analyses (P = 0.010), and incorporate 
elements of knowledge integration (P = 0.036). Approximately 74% of analyzed grants and 
publications involved discovery (T0) or characterization (T1) research, suggesting a need for more 
translational (T2–T4) research. Our evaluation indicated limited research in 1) a multilevel 
approach that incorporates molecular, individual, social, and environmental determinants and 2) 
knowledge integration that evaluates the robustness of scientific evidence. Cancer epidemiology is 
at the cusp of a paradigm shift, and the field will need to accelerate the pace of translating 
scientific discoveries in order to impart population health benefits. While multi-institutional and 
technology-driven collaboration is happening, concerted efforts to incorporate other key elements 
are warranted for the discipline to meet future challenges.
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We have previously observed that epidemiology is at the cusp of a paradigm shift—
propelled by a need to accelerate the pace of translating scientific discoveries to impart 
population health benefits (1). As part of a National Cancer Institute (NCI)-Epidemiology 
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and Genomics Research Program (EGRP) strategic planning effort to transform the practice 
of epidemiology in the 21st century, we identified a set of overarching “drivers” that can 
influence translational cancer epidemiology: 1) collaboration and team science; 2) emerging 
technology; 3) a multilevel approach; and 4) knowledge integration from basic, clinical, and 
population sciences (1).
Details related to each driver have been described elsewhere (1). In brief, the complexity 
and scope of cancer epidemiology research requires thoughtful team science initiatives 
across multiple disciplines (e.g., epidemiology, clinical medicine, statistics, environmental 
health, genomics, behavioral and social science, and health economics). This can be 
achieved, in part, by consortia of well-characterized cohort and case-control studies. 
Emerging technologies could facilitate better characterization of genomic background and 
exposures, as well as their interactions. A multilevel approach entails analyses and 
interventions that incorporate individual- and biological-level factors with 
macroenvironment-level factors to enhance the investigation of complex diseases (2, 3). 
Lastly, knowledge integration has been used with different definitions and perspectives (4–
6); for the present review, we adopted the definition that includes knowledge management, 
knowledge synthesis, and knowledge translation (7). Collectively the 3 processes provide a 
methodological framework for knowledge integration, which aims to maximize the use of 
collected scientific information to accelerate the translation of discoveries into individual 
and population health benefits and to identify scientific gaps that warrant further research 
(7).
We sought to obtain a snapshot of the types of studies being conducted in cancer 
epidemiology with respect to the “drivers” of such research in the first decade of the 21st 
century. Towards this goal, we undertook a systematic analysis of epidemiology-related 
grants funded by the NCI’s Division of Cancer Control and Population Sciences (DCCPS) 
and Division of Cancer Prevention (DCP) to assess the evolution of the identified “drivers” 
and the prevalence of translational cancer research in grants awarded through the NCI for 
the years 2000, 2005, and 2010. We performed the same analyses for a randomized sample 
of published literature across the 3 time periods. Here, we describe the results of the trends 
analysis of NCI-funded grant applications and peer-reviewed papers generated by the cancer 
epidemiology community and discuss the implications of our findings.
METHODS
Sampling frame for NCI grants
We focused our sampling frame on grants funded through the DCCPS and the DCP because 
collectively they represent a comprehensive selection of cancer epidemiology research 
supported by the NCI. The DCCPS and the DCP are 2 extramural divisions of the NCI. The 
DCCPS has the lead responsibility at NCI for supporting research in surveillance, 
epidemiology, health services, behavioral science, and cancer survivorship (http://
cancercontrol.cancer.gov/). Within the DCCPS, the EGRP is one of the largest funders of 
cancer epidemiology research in the United States (http://epi.grants.cancer.gov/). The DCP 
supports extramural research that generates new information about 1) molecular processes 
that are amenable to intervention, 2) developing effective chemo-prevention agents, 3) 
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discovering early detection biomarkers, 4) pinpointing mechanistically targeted nutrients, 5) 
testing new screening methods and technologies, and 6) conducting phase I, II, and III 
clinical trials in prevention and control (http://prevention.cancer.gov/).
Search for and selection of NCI grants
All grants funded through the DCCPS and DCP in the years 2000, 2005, and 2010 were 
analyzed. We used the NCI’s Portfolio Management Application software (version 13.4), 
which mines the National Institutes of Health IMPAC II database (http://era.nih.gov). We 
included only new and competing renewal grants for each year, regardless of funding 
mechanism. Because the focus of our analysis was to examine the evolution of the “drivers” 
in cancer epidemiology research, we included all grants awarded by the EGRP, whose 
mission is to fund research in human populations to further understanding of the 
determinants of cancer occurrence and its outcomes. For the other DCCPS programs and for 
DCP, we selected grants awarded for carrying out human studies with cancer-related 
endpoints. We excluded grants for studies that used animal models or cell lines or 
intervention studies with endpoints not related to cancer. Five coders performed the coding 
for the grants through a systematic review of the grant application’s abstract and specific 
aims. When needed, a review of the full grant application was conducted.
Literature search
We developed a specialized query (see Appendix) to search the PubMed database (National 
Library of Medicine, Bethesda, Maryland) for published studies related to cancer 
epidemiology. For the present project, our search algorithm was restricted to human studies 
described in English-language articles that included an abstract. We applied the search query 
for the years 2000, 2005, and 2010 separately. Three coders were assigned to each year, and 
each coder independently reviewed abstracts to identify the first 100 randomly selected 
cancer epidemiology publications in the assigned year. For our purposes, eligible studies 
must have had a cancer-related endpoint and a sample size of ≥100 cases. We excluded 
primary clinical trials but included meta-analyses of them. The first 100 cancer 
epidemiology studies identified for each of the years 2000, 2005, and 2010 were then 
compiled to form the 300 randomly selected publications for further coding.
Coding of grants and literature
Selected grants and publications were coded with regard to 5 key “drivers” and respective 
subcategories, as follows.
1. Emerging technology. Studies were assigned to the following technology 
subcategories: 1) none for studies using traditional exposure measurement tools 
(e.g., paper-based questionnaires); 2) single nucleotide polymorphism genotyping 
associated with candidate gene association studies and high-throughput genotyping 
associated with genome-wide association studies (GWAS); 3) other “-omics”-
related technologies (e.g., proteomes, telomere characteristics, methylation, 
mitochondrial DNA, micro-RNA, metabolomes); 4) novel technologies (studies 
that used geographic information systems or geospatial data or that incorporated/
developed novel statistical models, methods, or assays); and 5) other studies (e.g., 
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Web-based exposure assessment tools, imaging technology). These a priori 
subcategories were identified as those that have changed the landscape of 
epidemiologic research in the past decade.
2. Translational phases. Studies were assigned to the following subcategories: none, 
T0 phase for research that was etiological in nature (e.g., association studies), T1 
phase for research that characterized the health application of a scientific 
discovery, T2 phase for studies that evaluated the health application to inform 
development of a guideline, T3 phase for studies that researched the 
implementation, dissemination, or adaptation of the distribution of a tested 
intervention in different contexts, and T4 phase for studies that researched 
outcomes. Definitions of the phases of translation were derived from the work of 
Khoury et al. (8, 9) and modified appropriately for epidemiologic studies.
3. A multilevel approach. Subcategories included none for studies that examined a 
single exposure, gene-environment for studies that investigated the interplay 
between genes and modifiable risk factors, and other for studies that incorporated 
behavioral factors, social constructs, or geocoding factors into the model.
4. Knowledge integration. Subcategories included none, systematic review/meta-
analysis, and other for studies that included guideline development or development 
of tools, models, or databases. Both systematic reviews and meta-analysis were 
used as indicators of knowledge synthesis, a component of knowledge integration, 
which captures the integration of existing epidemiologic research on a particular 
topic (7). Development of guidelines and databases are broad indicators of 
knowledge management and knowledge translation (7).
5. Collaboration/team science. Studies were assigned to the following subcategories: 
none for single-institution case-control studies, case series, or family studies; 
cohort for studies using prospectively collected data from a single institution; and 
consortia for studies (case-control and/or cohort) formed through collaboration 
between multiple institutions (10).
Coders determined whether studies included any of the 5 broad categories and then assigned 
them to the appropriate subcategories. To minimize intercoder discrepancies in the literature, 
each coder reviewed one-third of the coding results for each of the other 2 years. Grants 
identified from each year were coded similarly with regard to the 5 areas and respective 
subcategories as described above. Additionally, the 4 primary coders reviewed one-quarter 
of the coding results for the other 2 years. Any disagreements were discussed as a group and 
resolved by consensus.
Statistical analyses
We created variables to represent the 5 broad “drivers.” We used consortium-based studies 
as an indicator of multi-institutional collaboration and by extension a surrogate for team 
science. We collapsed studies that used subcategories of technologies into 1 group, 
categorizing them as technology-driven, and compared them with those studies that did not 
use technologies (i.e., those that used traditional tools). Likewise, multilevel and knowledge 
integration variables were dichotomized into none versus yes (i.e., comprised of the 
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respective subcategories). We performed a modified Wilcoxon rank-sum test to examine 
trends across time periods (11). Exploratory analyses included investigating the relationship 
between collaboration (as the outcome of interest) and the remaining “drivers.” Analyses 
using 2-sample t tests were performed to compare differences. We used multivariate logistic 
regression, adjusting for year of funding or publication date and division (DCCPS or DCP), 
to examine the relationship between collaboration and selected drivers. All analyses were 
performed using Stata, version 10 (StataCorp LP, College Station, Texas).
RESULTS
Table 1 shows the coding results for NCI-funded grants and the published literature with 
respect to the 5 drivers of interest and their corresponding subcategories, by year (2000, 
2005, or 2010). We identified 591 cancer epidemiology–related grants funded through the 2 
NCI divisions in the 3 selected years. The DCCPS funded the majority (n = 443; 75%) of the 
identified cancer epidemiology grants; of these, the EGRP funded 58% (n = 256), while the 
other DCCPS programs funded the remaining 42% (data not shown). The number of cancer 
epidemiology grants funded by the NCI increased between 2000 and 2005 but declined 
slightly between 2005 and 2010. For the published literature, we reviewed a total of 1,710 
articles randomly selected from PubMed for the 3 specified years. From this random set, we 
identified 300 articles related to cancer epidemiology (i.e., 100 published studies per year).
Technology-driven research
Our data showed that funding of grants that incorporated contemporary technologies trended 
positively from 2000 to 2010 (Ptrend < 0.001; Table 1). Of those that used novel 
technologies, molecular technologies comprised the majority. Funding for GWAS research, 
for which the EGRP was the major source (10 of 11 grants), increased from 0% to 5.5% 
between 2005 and 2010. There was also an increasing trend for grants that incorporated 
other “-omic” technologies (Ptrend < 0.001), such as those for studies of methylation, 
proteomes, and mitochondrial DNA, acrossthe NCI. Funding of grants that used 
nonmolecular technologies also increased from 2000 to 2005 but decreased in 2010. In the 3 
years evaluated, few grants incorporated current technologies, such as mobile technologies, 
Web-based surveys, or electronic medical records.
In the cancer epidemiology literature, the proportion of studies that incorporated newer 
technologies was constant. Reports of GWAS findings appeared in 2010, and a sharp 
increase in findings from studies using other “-omic” technologies was observed between 
2005 (n = 1) and 2010 (n = 7). We observed a significant decline in the publication of 
findings from studies using nonmolecular technologies (Ptrend = 0.003).
Translational research
Overall, 74.1% (438/591) of all funded grants were for studies in the T0 (discovery) and T1 
(characterization) phases. The predominance of the discovery-characterization type of 
research supported by the NCI was evident in all 3 years evaluated. Although the finding 
was not statistically significant (Ptrend = 0.086), T1 research appeared to have been trending 
positively in recent years, withapproximately18.6% and 16.8% of new grants being T1 
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grants in 2005 and 2010 as compared with 9.8% in 2000. While numbers of T2 and T3 
grants appeared to be constant in the 3 years evaluated (approximately 7% per year), we 
observed a sizable number (n = 10; 6.1%) of T4 funded grants in 2000; however, there was a 
decrease in funding for these types of research in 2005 and 2010.
The literature analysis also showed that cancer epidemiology publications were 
predominantly (72.7%) studies in the discovery-characterization phase (T0/T1) (Table 1). In 
this random subset of 300 publications, approximately 6.3% were studies in the T2 phase 
and beyond. Among these, we identified 4 publications that encompassed elements of T4 
research, that is, outcome research representing the incorporation of evidence-based practice 
into a population health impact (Table 1).
Multilevel research
Only 19.3% (n = 114) of NCI grants and 7.3% of published studies incorporated a multilevel 
approach in our data set. Of those studies using a multilevel approach, the majority (60.1% 
for grants and 63.6% for the literature) were restricted to gene-environment interactions 
across the 3 single-year periods, with no evidence of a trend (Ptrend = 0.17). Beyond studies 
of gene-environment interaction, there was a decline in funded grants for studies using other 
types of approaches, such as studies incorporating sociocultural factors in addition to 
biological or lifestyle factors.
Conversely, the data showed a positive trend in the publication of gene-environment 
interaction research from 2000 to 2010 (Ptrend = 0.003), with a decreasing trend in 
multilevel approaches using other factors beyond gene-environment interaction.
Knowledge integration–related research
Thirty-four grants (5.8% of the total for the 3 years) included some component of 
knowledge integration. Of these, 6 grants (1.0% of the total) specified a planned meta-
analysis/systematic review (knowledge synthesis), while the remaining 28 were related to 
establishing database or guideline development (Table 1). While the proportions of grants 
incorporating knowledge synthesis (e.g., meta-analysis/systematic reviews) were marginal in 
the 3 single-year periods, there was a negative trend in funding of grants that related to 
guideline development or development of databases from disparate sources (Ptrend = 0.001).
For the literature analysis, we observed a notable decrease in the publication of narrative 
reviews between 2000 (17%) and 2010 (5%) (Ptrend = 0.013), while the proportion of 
systematic reviews and meta-analyses increased in the same period (Ptrend = 0.014).
Collaborative research
Overall, our evaluation of both NCI grants and the literature showed a distinct upward trend 
for multi-institutional collaborations in the form of consortia (for grants, Ptrend = 0.002; for 
literature, Ptrend = 0.006). The increase in consortium-related funding may have reflected the 
marked rise of findings from multi-institutional collaborative studies, which increased from 
0% prior to 2010 to 5% in 2010 (Table 1).
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Table 2 shows the relationships between the extent of collaboration and elements of the 
“drivers” in NCI grants. Compared with grants that were not cohort- or consortium-based, 
consortium-based grants were significantly more likely to incorporate emerging 
technologies (adjusted for year of funding and division, odds ratio (OR) = 1.79, 95% 
confidence interval (CI): 1.13, 2.82; P = 0.012), to support multilevel approaches (adjusted 
for year of funding and division, OR = 2.01, 95% CI: 1.18, 3.42; P = 0.010), and to support 
knowledge integration–type activities (adjusted for year of funding and division, OR = 2.57, 
95% CI: 1.06, 6.20; P = 0.036). For similar comparisons, cohort grants were also more 
likely to incorporate elements of novel technologies and multilevel approaches. For the 
literature analyses, we observed no difference in incorporation of technologies between 
cohort studies and collaborative consortium studies (P = 0.11).
DISCUSSION
In the present analysis, we evaluated the trends in cancer epidemiology publications and 
NCI-funded cancer epidemiology grants in relation to 5 characteristics or “drivers” of the 
field (1) for the years 2000, 2005, and 2010. Our evaluation of funded grants suggested an 
upward trend towards multi-institutional collaborative research and incorporation of novel 
technologies. For the published literature, there were significant positive trends toward 
consortium-based studies, systematic reviews/meta-analyses, and gene-environment studies. 
In the past decade, “-omic” technologies were generally the primary tools used in cancer 
epidemiology studies for both grants and literature. The present review has identified a 
critical need for more T2–T4 translational studies, multilevel analyses, and knowledge 
integration in the field of cancer epidemiology moving forward.
We and other investigators (1, 12, 13) have asserted that team science across disciplines and 
within fields is a critical component of 21st century cancer epidemiology research. Based on 
our review, the NCI’s support for multi-institutional collaborative research increased rapidly 
during the past decade. Furthermore, our analyses suggested that consortium-based studies 
may be the scientific engine driving the transformation of cancer epidemiology (1, 13). 
Nevertheless, a high proportion of the consortium grants restricted the research to molecular 
epidemiology–related inquiries. This is not surprising, since “-omic” technologies permeated 
cancer research in the first decade of the 21st century and cancer consortia were established 
at the end of the 20th century, primarily to overcome the issue of small sample sizes in 
cancer epidemiology. Thus, the original purpose of consortium-based research was to pool 
study data together to obtain the increased statistical precision afforded by a consortium’s 
larger sample size (14, 15) for discovery/etiological research in an era of genome-driven 
technologies.
The large sample sizes of consortia also explain the greater likelihood of consortia being 
awarded grants to engage in research using multilevel approaches, such as studies of gene-
environment interaction. Nonetheless, future collaborative endeavors should move beyond 
genome-based studies and fully optimize the full potential of consortia. An analysis of data 
collected from 49 EGRP-funded cancer epidemiology consortia recently highlighted several 
benefits of consortium-based research (10), including opportunities to form new 
collaborations or research networks across national boundaries. This modern scientific 
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enterprise may further facilitate the rapid incorporation of emerging technologies (as 
demonstrated by genome-wide genotyping and next-generation sequencing) into large-sale 
population studies and the capacity to integrate multilevel approaches (10).
There was limited evidence that incorporation of nonmolecular technologies is on the rise in 
our review. This will probably change, as current and future epidemiologic research needs to 
incorporate advancements in digital technology (e.g., smart phones, electronic medical 
records, and social media) to improve exposure assessment and outcome measurement. For 
example, we previously highlighted the potential for technologies used in dietary assessment 
to shed light on the equivocal evidence related to diet and cancer (1), and Kuller et al. have 
commented on the importance of new technologies that permit precise measurement of host 
and environmental exposures in epidemiology (16).
Our evaluation further suggests a critical gap in cancer epidemiology research with regard to 
knowledge integration and multilevel approaches. In the present review, we defined 
knowledge integration as comprised of 3 complementary processes (7), and we broadly used 
systematic reviews and meta-analyses as indicators of knowledge synthesis (a component of 
knowledge integration which assesses a synthesized body of evidence) and other elements of 
knowledge management and translation. Our analysis of the literature corroborated a prior 
analysis of the biomedical literature that found a decrease in narrative reviews and a marked 
positive trend in the publication of systematic reviews and meta-analyses (7). Collectively, 
the current state of epidemiologic publications suggests that more incorporation of 
knowledge integration is needed. This conclusion is further buttressed by a significant 
negative trend in NCI funding for knowledge integration during the past decade. Knowledge 
integration is needed to ensure that we effectively manage the accumulating data on a topic 
and analyze the insights that can be gleaned from them to inform the direction of future 
research.
Lynch and Rebbeck proposed a “Multilevel Biologic and Social Integrative Construct” (2, p. 
488) in which biological (e.g., genomic data) and individual (e.g., lifestyle, sociocultural, 
and behavioral data) factors are integrated with macroenvironmental factors (e.g., health-
care policies, neighborhoods) to fully characterize the complex nature of cancer risks and 
outcomes. Our review showed that the multilevel approach is currently limited to studies 
that have investigated the interaction between a few genes and 1 risk factor (e.g., smoking). 
As the field becomes more integrative in nature (17) and “big data” become more 
prominent, this area will have to expand, and leaders may need to critically address the 
challenges posed by big data and determine how to actualize this framework in practice. For 
example, the questions of how to integrate germ-line and somatic genomic information 
coupled with environmental exposures will become more complicated when the 
macroenvironmental factors are considered.
Our review suggested that there is a critical gap in advanced translational research in cancer 
epidemiology, as much of the discipline’s research is anchored in the T0 (discovery) and T1 
(characterization) phases. Our findings confirmed those of a previous report that only 1.8% 
of research in cancer genomics was conducted in the later phases of translation (18). Moving 
discovery research through the translational continuum is a logical framework for T0/T1 
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research in order to impart population impact through the subsequent T2–T4 phases. The 
lack of downstream translational research in cancer epidemiology may create a self-imposed 
boundary in the field and may inadvertently lessen its relevance to the larger scientific 
community. Research beyond the T0/T1 realm can extend the scope of the field, identify 
where epidemiologic concepts and principles can be applied, and inform guidelines and 
policy. However, we stress that our emphasis on translation should not diminish the 
importance of etiological research, nor does it imply that the conduct of more advanced 
translational research should fall solely on the shoulders of cancer epidemiologists.
Many of the past discoveries that have revolutionized science have been made by accident 
(e.g., penicillin and radioactivity); however, epidemiologic research, by virtue of its study of 
free-living populations in variable environments, cannot afford to rely on accidental 
findings. Rather, epidemiologists should engage in a thoughtful process to apply potential 
findings in the context of a more complex world. Our portfolio analyses also highlighted the 
complementary roles of the different programs within the DCCPS and DCP in supporting 
epidemiologic investigations across the translational research continuum. While the EGRP 
funds primarily etiological cancer epidemiology, other programs in the DCCPS fund more 
downstream translational research (T1 and beyond). This further underscores the importance 
of collaboration between cancer epidemiologists and investigators in other disciplines (e.g., 
health economics, behavioral science, health services, biology) and the need to robustly 
engage in team science as cancer epidemiology moves further into the 21st century.
The present findings present a cross-sectional snapshot of the types of research being 
conducted in cancer epidemiology and therefore do not reflect the breadth of the field. While 
the NCI is a significant funder of cancer epidemiology research in the United States, the 
grants we analyzed were reflective only of studies funded by the NCI, not of studies funded 
through other sources (e.g., the US Department of Defense, the Centers for Disease Control 
and Prevention, or private foundations). Other funders may support epidemiologic research 
that lies further downstream on the translational research continuum. Moreover, the NCI 
primarily funds US-based investigators; thus, our review did not capture the research funded 
by our international counterparts. It is also likely that we missed proposed applications for 
epidemiologic research submitted to the NCI that were transformative and that included 
elements of the identified “drivers” but did not score well when reviewed by the National 
Institutes of Health’s Study Sections and thus were not included in our analysis of funded 
grants. Likewise, the publications we analyzed may have reflected the work derived from 
funded research and/or accepted by peer reviewers but not all of the papers submitted to 
PubMed journals. It is possible that an evaluation of trends in submitted grant proposals and 
articles would suggest a different landscape with respect to the “drivers” of cancer 
epidemiology research. Nevertheless, such a review would have been challenging and was 
beyond the scope of our present analyses. The review and the findings presented reflect the 
funded research (in grants and publications) that successfully passed through the peer-
review process at the NCI and the PubMed journals, respectively.
Limiting our analyses of literature and grants to the years leading up to and including 2010 
might not have presented an accurate picture of the current landscape in cancer 
epidemiology. It is highly possible that there are currently more multi-institutional 
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collaborative publications—a direct result of more funding for consortia in 2010—that were 
not part of our analyses. Similarly, studies using GWAS-related technologies will have 
diminished, as funding for GWAS studies has dropped significantly since 2010, when more 
funding was allotted to post-GWAS grants. Lastly, our analyses may not have fully captured 
the entirety of translational research, particularly the advanced phases (T2 and beyond) of 
translation. It is possible that T2–T4 research may not involve the types of studies 
traditionally considered epidemiologic, although they may be informed by epidemiologic 
findings. Nevertheless, we analyzed grants supported by the DCCPS and DCP, and 
collectively, grants funded by these 2 divisions of the NCI should have represented a major 
proportion of cancer epidemiology studies conducted nationally and worldwide during the 
first decade of the 21st century.
The landscape of cancer epidemiology research has changed, and concrete recommendations 
have been made to the scientific community that, if incorporated, promise to transform the 
field and transition it further into the 21st century (13). While our analyses focused on 
cancer epidemiology, our findings provide evidence in support of such endeavors by 
highlighting critical areas that warrant more focused efforts by the epidemiology community 
at large, particularly with regard to the translational potential of a proposed study within the 
research continuum.
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APPENDIX
Algorithm Used in PubMed Literature Search
The following algorithm was used to search PubMed for cancer epidemiology studies 
published in the years 2000, 2005, and 2010.
(Cancer[TIAB] OR leukemia[TIAB] OR lymphoma[TIAB] OR malignancy[TIAB] OR 
malignancies[TIAB] OR adenoma[TIAB] OR blastoma[TIAB] OR tumor[TIAB] OR 
tumour[TIAB] OR cancers[TIAB] OR neoplasms OR melanoma[TIAB] OR 
myeloma[TIAB] OR carcinoma[TIAB] OR neoplasia[TIAB] or adenocarcinoma[TIAB] OR 
sarcoma[TIAB] OR glioma[TIAB] OR craniopharyngioma[TIAB] OR ependymoma[TIAB] 
Lam et al. Page 11













OR Cholangiocarcinoma[TIAB]) AND (neoplasms/ep OR “epidemiology” [MeSH Terms] 
OR “epidemiologic methods”[MeSH Terms] OR epidemiology[Text Word] OR 
“prospective cohort” OR “multi-cohort” OR “multiple-cohort” OR “retrospective cohort” 
OR ((patients OR cases) AND controls) OR ((retrospective[Text Word] OR 
prospective[Text Word] OR “cross-section” [Text Word] OR “cross-sectional” [Text Word] 
OR “case-control” [Text Word]) AND (cohort[Text Word] OR studies[TIAB] OR 
study[TIAB])) OR “randomized controlled trial” [TIAB] OR ((patients OR “patient group” 
OR women OR men OR participants OR adult OR children) AND ((matched pairs AND 
tissue) OR retrospective OR retrospectively OR prospectively OR prospective OR “clinical 
trial” OR “clinical trials” OR “p<0.” [TIAB] OR (correlation[Text Word] AND 
study[TIAB]) OR cohort OR cohorts OR protocol OR population OR “control subjects” OR 
“healthy subjects” OR “all patients” OR individuals OR eligible OR randomly assigned OR 
(series AND cases) OR “odds ratio” OR “hazards ratio” OR “relative risk” OR data OR 
positive predictive value OR “receiver operating characteristic” OR “z statistic”)) OR 
(“Genome-Wide Association” OR GWAS OR “meta-analysis” OR “meta-analyses” OR 
“random-effect model” OR “systematic review” OR IARC) OR ((“Phase 1”[Text Word] OR 
“Phase I”[Text Word] OR “Phase II”[Text Word] OR “Phase 2” [Text Word] OR “phase 
III”[Text Word] OR “phase 3”[Text Word]) AND (study[TIAB] OR trial[TIAB])) OR 
“univariate analysis” OR “multivariate analysis” OR “positive predictive value” [Text 
Word] OR “negative predictive value” [Text Word] OR “odds ratio” OR “causal 
association” OR “population based” OR “Kaplan Meier”) NOT (Comment[pt] OR Case 
Reports[pt] OR Editorial[pt] OR News[pt]) AND “2000”[PDAT]*
For the years 2005 and 2010, “2005[PDAT]*” and “2010[PDAT]*” were substituted for the 
last element of the query.
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